The problems developed in women given the standard intravenous drug doxorubicin along with a newer drug called docetaxel. The two drugs are frequently used alone to treat breast cancer. Scientists have been exploring the effects of combining them, with mixed results so far.
Docetaxel, or Taxotere, belongs to a class of cancer drugs that also includes Taxol. These drugs are derived from the yew tree and have shown promise in improving cancer survival.
French researchers set out to compare five-year, disease-free survival rates in 627 women treated with either doxorubicin plus Taxotere or the more conventional combination of doxorubicin plus cyclophosphamide. But they stopped the study after a little over three years, in 2003.
The patients who died had developed low white blood cell counts, fever and severe intestinal problems. A third woman became severely ill with similar symptoms.